Comparative Pharmacology
Head-to-head clinical analysis: SELENIUM SULFIDE versus VANOBID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELENIUM SULFIDE versus VANOBID.
SELENIUM SULFIDE vs VANOBID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selenium sulfide is an antifungal and cytostatic agent. It reduces sebum production and inhibits the growth of Malassezia species by interfering with fungal lipid metabolism and cell wall synthesis. The exact molecular mechanism is not fully elucidated.
Vancomycin inhibits cell wall synthesis by binding to the D-alanyl-D-alanine terminus of peptidoglycan precursors, preventing cross-linking.
Topical: 2.5% lotion or shampoo applied to affected area once daily for 7 days; 1% shampoo used once or twice weekly for maintenance.
500-1000 mg orally every 12 hours or 250 mg every 6 hours.
None Documented
None Documented
Not established; due to negligible systemic absorption, a terminal half-life is not clinically relevant. If absorbed, selenium has a long biological half-life of approximately 65–115 days due to incorporation into selenoproteins.
Terminal elimination half-life: 8-12 hours in patients with normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Selenium sulfide is minimally absorbed after topical application. The small absorbed fraction is excreted renally as selenite or selenate, with fecal excretion of unabsorbed drug accounting for >90% of the dose.
Renal (unchanged): 30-50% within 24 hours; Biliary/fecal: 15-25% as metabolites; remainder undergoes hepatic metabolism.
Category A/B
Category C
Antifungal / Antiseborrheic
Antifungal and Corticosteroid Combination